Clinical Trial

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis

Completed Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate TQC2938 injection in all patients receiving background treatment with azelastine fluticasone nasal spray. The efficacy, safety and immunogenicity of the injection in patients with seasonal allergic rhinitis compared with placebo are expected to include 136 patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-26; most recent amendment 2026-02-08.
Status change: Recruiting → Completed 2026-02-08
Status change: Not Yet Recruiting → Recruiting 2025-08-18
Trial Details
NCT Number NCT07052097
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Seasonal Allergic Rhinitis
Enrollment 136 participants
Start Date 2025-07-31
Primary Completion 2025-09-12 (estimated)
Study Completion 2025-11-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-10